Sulfathiazole
DERMATOLOGICALS
Also known as: norsulfasol, norsulfazol, norsulfazole, sulfanilamidothiazole, sulfathiazol, sulphathiazole, thiazamide, thiozamide
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Sulfathiazole is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1945. DrugCentral lists 4 molecular targets, including folP, lasR and EDNRA. Recorded indications include Gardnerella Vaginalis Bacterial Vaginosis and Vulvovaginitis.
- Approval status: ofm (first approved 1945 by the FDA).
- Molecular targets: folP, lasR, EDNRA and Ednra (4 listed in DrugCentral).
- Indications: Gardnerella Vaginalis Bacterial Vaginosis and Vulvovaginitis.
- ATC code: D06BA02 (Sulfonamides).
- Molecular formula: C9H9N3O2S2; molecular weight 255.31 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Gardnerella Vaginalis Bacterial Vaginosis
- Vulvovaginitis
Contraindications (7)
- Anemia due to enzyme deficiency
- Breastfeeding (mother)
- Deficiency of glucose-6-phosphate dehydrogenase
- Disease of blood AND/OR blood-forming organ
- Disease of liver
- Kidney disease
- Porphyria
Mechanism & targets
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Dihydropteroate synthase | folP | inhibitor | IC50 5.60 |
| Transcriptional activator protein LasR | lasR | unknown | IC50 5.05 |
| Endothelin-1 receptor | EDNRA | unknown | IC50 4.16 |
| Endothelin-1 receptor | Ednra | unknown | IC50 4.16 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1945-09-12 | FDA | — | ORTHO MCNEIL PHARM |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D06BA02 | DERMATOLOGICALS › ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE › CHEMOTHERAPEUTICS FOR TOPICAL USE › Sulfonamides |
J01EB07 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › SULFONAMIDES AND TRIMETHOPRIM › Short-acting sulfonamides |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Subcutaneous drug absorption impaired | 372.4 |
| General symptom | 326.7 |
| Pustular psoriasis | 324.0 |
| Rash vesicular | 321.7 |
| Breast cancer stage II | 313.2 |
| Back disorder | 273.3 |
| Adjustment disorder with depressed mood | 263.4 |
| Dislocation of vertebra | 262.0 |
| Myositis | 261.8 |
| Folliculitis | 239.7 |
| Wound infection | 236.8 |
| Joint range of motion decreased | 229.9 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Sulfathiazole is on its molecule page.
| Molecular formula | C9H9N3O2S2 |
|---|---|
| Molecular weight | 255.31 g/mol |
| CAS number | 72-14-0 |
| InChIKey | JNMRHUJNCSQMMB-UHFFFAOYSA-N |
| PubChem CID | 5340 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Sulfathiazole used for?
DrugCentral lists the following indications for Sulfathiazole: Gardnerella Vaginalis Bacterial Vaginosis and Vulvovaginitis.
How does Sulfathiazole work?
Its molecular targets in DrugCentral include folP (inhibitor), lasR, EDNRA and Ednra.
When was Sulfathiazole first approved?
Sulfathiazole was first approved by the FDA in 1945.
What is the chemical formula of Sulfathiazole?
Sulfathiazole has the molecular formula C9H9N3O2S2 and a molecular weight of 255.31 g/mol.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2527 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL437 — compound record and bioactivity
- PubChem CID 5340 — chemical identifiers
- DrugBank DB06147 — drug record
- FDA UNII Y7FKS2XWQH — substance identity
- DailyMed: FDA labels for Sulfathiazole — current prescribing information (label search)
- UniProt P25101 (EDNRA) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.